Inhaled Insulin
Phase 3Small molecule
PfizerInhaled Insulin is one of 147 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 3.
6
Indications
35
Total Trials
0
Active Trials
146
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Inhaled Insulin
PfizerPhase 3
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Arcoxia
NovartisPreclinical
Aciphex
Akero TherapeuticsPreclinical
Blood Withdrawn
Emergent BioSolutionsPreclinical
Spiriva
Boehringer IngelheimPreclinical
Allergen Immunotherapy Extract
JJohns Hopkins University
Preclinical
Biological Drug
UUniversitaire Ziekenhuizen KU Leuven
Preclinical
FP/SAL
GSKPreclinical
Inhaled Albuterol
NNational Heart, Lung, and Blood Institute (NHLBI)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Type 2 Diabetes8 trials
Show 5 more trials
Type 1 Diabetes7 trials
Show 4 more trials
Efficacy and Safety4 trials
Clinical Trial3 trials
Asthma3 trials
7 more indications
Type 2 Diabetes Mellitus3 trials
Diabetes2 trials
Oral1 trial
Type 1 Diabetes Mellitus1 trial
Chronic Obstructive Pulmonary Disease1 trial
Metformin1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Inhaled Insulin. EMBL-EBI & Wellcome Sanger Institute.
- [4]